<?xml version="1.0" encoding="utf-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:aimd="http://aimd.com/20220331" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><head><title>aimd_10k.htm</title><!--Document Created by XBRLMaster--><meta content="text/html" http-equiv="Content-Type"/></head><body style="text-align:left;font:10pt times new roman"><div id="XBRLDIV" style="display:none;color:#000000;text-align:left;font:10pt times new roman;"><ix:header><ix:hidden><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityCentralIndexKey">0001014763</ix:nonnumeric><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonnumeric><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonnumeric><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonnumeric><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonnumeric><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" name="us-gaap:PreferredStockValue" unitref="USD">0</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" name="us-gaap:PreferredStockValue" unitref="USD">0</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares">0.01</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="0" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares">10000000000000</ix:nonfraction><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" name="us-gaap:PreferredStockSharesIssued" unitref="Shares">0</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="0" name="us-gaap:PreferredStockSharesIssued" unitref="Shares">0</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="USDPShares">0.01</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="0" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">300000000</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="0" name="us-gaap:CommonStockSharesIssued" unitref="Shares">144379308</ix:nonfraction><ix:nonfraction contextref="AsOf2021-12-30" decimals="0" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares">144379308</ix:nonfraction><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" name="us-gaap:CommonStockSharesOutstanding" unitref="Shares">144379308</ix:nonfraction><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="INF" name="aimd:AnnualInterestRateFollowingMaturity" unitref="Pure">0.1</ix:nonfraction><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" decimals="INF" name="aimd:AnnualInterestRateFollowingMaturity" unitref="Pure">0.1</ix:nonfraction></ix:hidden><ix:references><link:schemaref xlink:href="aimd-20220331.xsd" xlink:type="simple"></link:schemaref></ix:references><ix:resources><xbrli:context id="From2022-01-01to2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2027-03-30_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2027-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-28_aimd_ChihHengTsaiMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aimd:ChihHengTsaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_YunHanLiaoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aimd:YunHanLiaoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-03-01to2022-03-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-03-01</xbrli:startdate><xbrli:enddate>2022-03-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EightBTwoZeroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NineTwoOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TotalMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TotalMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyFourTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwentyThreeMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyThreeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwentyOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NinteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EighteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SeventeenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SixteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FifteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FourteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:ThirteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwelveTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwoOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:OneOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EightBTwoZeroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NineTwoOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyFourTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyThreeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwentyOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NinteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EighteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SeventeenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SixteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FifteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FourteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:ThirteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwelveTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwoOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:OneOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentySixTwoTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentySixTwoTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EightBTwoZeroMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NineTwoOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TotalMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TotalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyFourTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyThreeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwentyOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwentyTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:NinteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:EighteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SeventeenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:SixteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FifteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:FourteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:ThirteenTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwelveTwoOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:AinosKYMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:TwoOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">aimd:OneOneSixMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_CommonStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">aimd:CommonStocksMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_aimd_OtherComprehensiveIncomesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">aimd:OtherComprehensiveIncomesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_aimd_OtherComprehensiveIncomesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">aimd:OtherComprehensiveIncomesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2022-01-01to2022-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_aimd_OtherComprehensiveIncomesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">aimd:OtherComprehensiveIncomesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_aimd_OtherComprehensiveIncomesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">aimd:OtherComprehensiveIncomesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-05-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:DocumentType">10-Q</ix:nonnumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Mark One)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> <ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport">☑</ix:nonnumeric>  <strong>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the quarterly period ended <ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 31, 2022</ix:nonnumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>or</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport">☐</ix:nonnumeric>   <strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the transition period from _____ to _____</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Commission File No.</strong><strong> <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityFileNumber">0-20791</ix:nonnumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityRegistrantName">AINOS, INC.</ix:nonnumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Exact name of registrant as specified in its charter)</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonnumeric></strong></p></td><td style="width:10%;"></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityTaxIdentificationNumber">75-1974352</ix:nonnumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> incorporation or organization)</p></td><td></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="3" style="width:78%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine1">8880 Rio San Diego Drive</ix:nonnumeric>, <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityAddressAddressLine2">Ste. 800</ix:nonnumeric>, <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityAddressCityOrTown">San Diego</ix:nonnumeric>, <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityAddressStateOrProvince">CA</ix:nonnumeric> <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityAddressPostalZipCode">92108</ix:nonnumeric> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:CityAreaCode">858</ix:nonnumeric>) <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:LocalPhoneNumber">869-2986</ix:nonnumeric></span></strong></p></td></tr><tr style="height:15px"><td colspan="3" style="width:78%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address and telephone number, including area code, of registrant's principal executive offices)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonnumeric> ☐ No</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ <ix:nonnumeric contextref="From2022-01-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonnumeric>   ☐ No </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">☐</p></td><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer</p></td><td style="width:20%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">☐</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonnumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">☑</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness">☑</ix:nonnumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">☐</ix:nonnumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) <ix:nonnumeric contextref="From2022-01-01to2022-03-31" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany">☐</ix:nonnumeric> Yes  ☑ No</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="AsOf2022-05-16" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" unitref="Shares">144,379,308</ix:nonfraction> shares of common stock, par value $0.01 per share, outstanding as of May 16, 2022 </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AINOS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" id="toc" style="display: inline">INDEX</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">PAGE NO.</span></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p1">PART I:</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p1">FINANCIAL INFORMATION</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1">ITEM 1.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1">Financial Statements</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#bs">Condensed Consolidated Balance Sheets– March 31, 2022 and December 31, 2021 (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sop">Condensed Consolidated Statements of Operations – Three Months Ended March 31, 2022 and 2021 (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#loss">Condensed Consolidated Statements of Comprehensive Loss – Three Months Ended March 31, 2022 and 2021 (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#stock">Condensed Consolidated Statements of Stockholders’ Equity (Deficit) – Three Months Ended March 31, 2022 and 2021 (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#cf">Condensed Consolidated Statements of Cash Flows – Three Months Ended March 31, 2022 and 2021 (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">7</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#note">Notes to Financial Statements (unaudited)</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">ITEM 2.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">13</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">ITEM 3.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Quantitative and Qualitative Disclosures About Market Risk</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">17</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">ITEM 4.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Controls and Procedures</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">17</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2">PART II:</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#p2">OTHER INFORMATION</a></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1n">ITEM 1.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1n">Legal Proceedings</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">18</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1a">ITEM 1A.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1a">Risk Factors</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2n">ITEM 2.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2n">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3n">ITEM 3.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3n">Defaults Upon Senior Securities</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4n">ITEM 4.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4n">Mine Safety Disclosures</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i5n">ITEM 5.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i5n">Other Information</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">19</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">ITEM 6.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">Exhibits</a></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sin">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">22</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="p1" style="display: inline">PART I - FINANCIAL INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i1" style="display: inline">ITEM 1. Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="bs" style="display: inline">Ainos, Inc.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Condensed Consolidated Balance Sheets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">1,871,349</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">1,751,499</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_4" name="us-gaap:InventoryGross" unitref="USD">337,805</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:zerodash" id="fid_5" name="us-gaap:InventoryGross" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitref="USD">813,905</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_7" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitref="USD">466,198</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_8" name="us-gaap:AssetsCurrent" unitref="USD">3,023,059</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_9" name="us-gaap:AssetsCurrent" unitref="USD">2,217,697</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Intangible assets, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_10" name="us-gaap:IntangibleAssetsCurrent" unitref="USD">36,214,023</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_11" name="us-gaap:IntangibleAssetsCurrent" unitref="USD">37,329,191</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_12" name="us-gaap:PropertyPlantAndEquipmentNet" unitref="USD">1,419,584</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_13" name="us-gaap:PropertyPlantAndEquipmentNet" unitref="USD">1,187,702</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other assets </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_14" name="us-gaap:OtherAssetsNoncurrent" unitref="USD">79,598</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_15" name="us-gaap:OtherAssetsNoncurrent" unitref="USD">87,571</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_16" name="us-gaap:Assets" unitref="USD">40,736,264</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_17" name="us-gaap:Assets" unitref="USD">40,822,161</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Liabilities and Stockholders' Equity </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible notes payable </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_20" name="us-gaap:ConvertibleNotesPayableCurrent" unitref="USD">3,376,526</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_21" name="us-gaap:ConvertibleNotesPayableCurrent" unitref="USD">3,376,526</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_22" name="us-gaap:NotesPayable" unitref="USD">1,013,405</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_23" name="us-gaap:NotesPayable" unitref="USD">213,405</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses and others current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_24" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitref="USD">1,339,585</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_25" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitref="USD">1,004,868</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payables – related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:zerodash" id="fid_26" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_27" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" unitref="USD">26,000,000</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_28" name="us-gaap:LiabilitiesCurrent" unitref="USD">5,729,516</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_29" name="us-gaap:LiabilitiesCurrent" unitref="USD">30,594,799</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long term liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible notes payable - noncurrent</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_57" name="aimd:ConvertibleNotesPayableNoncurrent" unitref="USD">26,900,000</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:zerodash" id="fid_58" name="aimd:ConvertibleNotesPayableNoncurrent" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities - noncurrent</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_33" name="us-gaap:OperatingLeaseLiabilityCurrent" unitref="USD">24,152</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_34" name="us-gaap:OperatingLeaseLiabilityCurrent" unitref="USD">30,255</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total long term liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_35" name="us-gaap:LiabilitiesNoncurrent" unitref="USD">26,924,152</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_36" name="us-gaap:LiabilitiesNoncurrent" unitref="USD">30,255</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_37" name="us-gaap:Liabilities" unitref="USD">32,653,668</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_38" name="us-gaap:Liabilities" unitref="USD">30,625,054</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Stockholders' equity </strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Preferred stock, $<ix:nonfraction contextref="AsOf2022-03-31" decimals="INF" format="ixt:numdotdecimal" id="fid_59" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitref="USDPShares">0.01</ix:nonfraction> par value; <ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_61" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares">10,000,000</ix:nonfraction> shares </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">authorized; none issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock, $<ix:nonfraction contextref="AsOf2022-03-31" decimals="INF" format="ixt:numdotdecimal" id="fid_67" name="us-gaap:CommonStockParOrStatedValuePerShare" unitref="USDPShares">0.01</ix:nonfraction> par value; <ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_69" name="us-gaap:CommonStockSharesAuthorized" unitref="Shares">300,000,000</ix:nonfraction> shares</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">authorized as of March 31, 2022 and December 31,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">2021; <ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_71" name="us-gaap:CommonStockSharesIssued" unitref="Shares">144,379,308</ix:nonfraction> shares issued and outstanding as</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">of March 31, 2022 and December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_45" name="us-gaap:CommonStockValue" unitref="USD">1,443,793</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_46" name="us-gaap:CommonStockValue" unitref="USD">1,443,793</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_47" name="us-gaap:AdditionalPaidInCapital" unitref="USD">18,899,873</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_48" name="us-gaap:AdditionalPaidInCapital" unitref="USD">18,856,430</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_49" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" unitref="USD">12,208,811</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_50" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" unitref="USD">10,108,916</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation adjustment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_51" name="aimd:TranslationAdjustmentLiability" sign="-" unitref="USD">52,259</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_52" name="aimd:TranslationAdjustmentLiability" unitref="USD">5,800</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total stockholders’ equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_53" name="us-gaap:StockholdersEquity" unitref="USD">8,082,596</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_54" name="us-gaap:StockholdersEquity" unitref="USD">10,197,107</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities and stockholders’ equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_55" name="us-gaap:LiabilitiesAndStockholdersEquity" unitref="USD">40,736,264</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_56" name="us-gaap:LiabilitiesAndStockholdersEquity" unitref="USD">40,822,161</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to condensed consolidated financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="sop" style="display: inline">Condensed Consolidated Statements of Operations </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_75" name="us-gaap:Revenues" unitref="USD">87,200</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_76" name="us-gaap:Revenues" unitref="USD">2,121</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_77" name="us-gaap:CostOfRevenue" unitref="USD">41,078</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_78" name="us-gaap:CostOfRevenue" unitref="USD">1,249</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gross margin </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_79" name="us-gaap:GrossProfit" unitref="USD">46,122</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_80" name="us-gaap:GrossProfit" unitref="USD">872</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_82" name="us-gaap:ResearchAndDevelopmentExpense" unitref="USD">1,577,454</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_83" name="us-gaap:ResearchAndDevelopmentExpense" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Selling, general and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_84" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitref="USD">551,730</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_85" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitref="USD">522,981</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_86" name="us-gaap:OperatingExpenses" unitref="USD">2,129,184</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_87" name="us-gaap:OperatingExpenses" unitref="USD">522,981</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_88" name="us-gaap:OperatingIncomeLoss" sign="-" unitref="USD">2,083,062</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_89" name="us-gaap:OperatingIncomeLoss" sign="-" unitref="USD">522,109</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-operating income and expenses, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest expenses, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_91" name="us-gaap:InterestRevenueExpenseNet" sign="-" unitref="USD">16,687</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_92" name="us-gaap:InterestRevenueExpenseNet" sign="-" unitref="USD">11,897</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_93" name="us-gaap:OtherExpenses" unitref="USD">146</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_94" name="us-gaap:OtherExpenses" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total non-operating income and expenses, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_95" name="aimd:TotalNonOperatingIncomeAndExpenses" sign="-" unitref="USD">16,833</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_96" name="aimd:TotalNonOperatingIncomeAndExpenses" sign="-" unitref="USD">11,897</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_97" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">2,099,895</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_98" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per average share available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="INF" format="ixt:numdotdecimal" id="fid_99" name="aimd:EarningPerShareBasicAndDiluted" sign="-" unitref="USDPShares">0.01</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="INF" format="ixt:numdotdecimal" id="fid_100" name="aimd:EarningPerShareBasicAndDiluted" sign="-" unitref="USDPShares">0.01</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding– basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_101" name="aimd:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" unitref="Shares">144,379,308</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_102" name="aimd:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" unitref="Shares">42,066,172</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to condensed consolidated financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="loss" style="display: inline">Condensed Consolidated Statements of Comprehensive Loss</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_846" name="aimd:NetLoss" sign="-" unitref="USD">2,099,895</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_847" name="aimd:NetLoss" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other comprehensive loss:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Translation adjustment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_848" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitref="USD">58,059</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_852" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Comprehensive loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_850" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" unitref="USD">2,157,954</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_851" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to condensed consolidated financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="stock" style="display: inline">Condensed Consolidated Statements of Stockholders’ Equity (Deficit)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the three months ended March 31, 2022 and 2021</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Unaudited)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Other comprehensive </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Stockholders’ Equity </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>loss</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Deficit)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_112" name="us-gaap:StockholdersEquity" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_111" name="us-gaap:SharesIssued" unitref="Shares">144,379,308</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_113" name="us-gaap:StockholdersEquity" unitref="USD">1,443,793</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_114" name="us-gaap:StockholdersEquity" unitref="USD">18,856,430</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_115" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">10,108,916</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31_aimd_OtherComprehensiveIncomesMember" decimals="0" format="ixt:numdotdecimal" id="fid_116" name="us-gaap:StockholdersEquity" unitref="USD">5,800</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_117" name="us-gaap:StockholdersEquity" unitref="USD">10,197,107</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_118" name="us-gaap:DividendsShareBasedCompensation" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_120" name="us-gaap:DividendsShareBasedCompensation" unitref="USD">43,443</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_123" name="us-gaap:DividendsShareBasedCompensation" unitref="USD">43,443</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_124" name="us-gaap:NetIncomeLoss" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_127" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">2,099,895</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_129" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">2,099,895</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation Adjustment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_OtherComprehensiveIncomesMember" decimals="0" format="ixt:numdotdecimal" id="fid_134" name="aimd:TranslationAdjustment" sign="-" unitref="USD">58,059</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_135" name="aimd:TranslationAdjustment" sign="-" unitref="USD">58,059</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at March 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_138" name="us-gaap:StockholdersEquity" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_137" name="us-gaap:SharesIssued" unitref="Shares">144,379,308</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_139" name="us-gaap:StockholdersEquity" unitref="USD">1,443,793</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_140" name="us-gaap:StockholdersEquity" unitref="USD">18,899,873</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2022-03-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_141" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">12,208,811</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2022-03-31_aimd_OtherComprehensiveIncomesMember" decimals="0" format="ixt:numdotdecimal" id="fid_142" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">52,259</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_143" name="us-gaap:StockholdersEquity" unitref="USD">8,082,596</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_146" name="us-gaap:StockholdersEquity" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_145" name="us-gaap:SharesIssued" unitref="Shares">42,066,172</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_147" name="us-gaap:StockholdersEquity" unitref="USD">420,662</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_148" name="us-gaap:StockholdersEquity" unitref="USD">4,961,315</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_149" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">6,220,255</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_151" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">838,278</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_154" name="us-gaap:DividendsShareBasedCompensation" unitref="USD">94,105</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_157" name="us-gaap:DividendsShareBasedCompensation" unitref="USD">94,105</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_161" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_163" name="us-gaap:NetIncomeLoss" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance at March 31, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31_us-gaap_PreferredStockMember" decimals="0" format="ixt:zerodash" id="fid_166" name="us-gaap:StockholdersEquity" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_165" name="us-gaap:SharesIssued" unitref="Shares">42,066,172</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31_us-gaap_CommonStockMember" decimals="0" format="ixt:numdotdecimal" id="fid_167" name="us-gaap:StockholdersEquity" unitref="USD">420,662</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" decimals="0" format="ixt:numdotdecimal" id="fid_168" name="us-gaap:StockholdersEquity" unitref="USD">5,055,420</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2021-03-31_us-gaap_RetainedEarningsMember" decimals="0" format="ixt:numdotdecimal" id="fid_169" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">6,754,261</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31_aimd_OtherComprehensiveIncomesMember" decimals="0" format="ixt:zerodash" id="fid_170" name="us-gaap:StockholdersEquity" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="AsOf2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_171" name="us-gaap:StockholdersEquity" sign="-" unitref="USD">1,278,179</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to condensed consolidated financial statements</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="cf" style="display: inline">Condensed Consolidated Statements of Cash Flows </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash flows from operating activities：</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_231" name="us-gaap:ProfitLoss" sign="-" unitref="USD">2,099,895</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_232" name="us-gaap:ProfitLoss" sign="-" unitref="USD">534,006</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating. activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_176" name="us-gaap:CostDepreciationAmortizationAndDepletion" unitref="USD">1,168,773</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_177" name="us-gaap:CostDepreciationAmortizationAndDepletion" unitref="USD">3,905</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Share-based compensation expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_178" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="USD">43,443</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_179" name="us-gaap:AllocatedShareBasedCompensationExpense" unitref="USD">94,105</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_181" name="us-gaap:InventoryWriteDown" sign="-" unitref="USD">337,805</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_182" name="us-gaap:InventoryWriteDown" unitref="USD">3,024</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_183" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitref="USD">297,707</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_184" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" sign="-" unitref="USD">18,254</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses and others current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_185" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitref="USD">133,302</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_186" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitref="USD">202,981</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_187" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" unitref="USD">1,389,889</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_188" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" unitref="USD">211,737</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash flows from investing activities：</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Acquisition of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_190" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitref="USD">135,899</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_191" name="us-gaap:PaymentsToAcquireOtherPropertyPlantAndEquipment" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_192" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" unitref="USD">135,899</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_193" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash flows from financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from convertible notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_195" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" unitref="USD">850,000</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_196" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" unitref="USD">236,854</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_197" name="us-gaap:ProceedsFromNotesPayable" unitref="USD">800,000</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_198" name="us-gaap:ProceedsFromNotesPayable" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of other notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:zerodash" id="fid_199" name="us-gaap:RepaymentsOfNotesPayable" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_200" name="us-gaap:RepaymentsOfNotesPayable" unitref="USD">37,985</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_201" name="aimd:PaymentsOfLeaseLiabilities" unitref="USD">5,116</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_202" name="aimd:PaymentsOfLeaseLiabilities" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_203" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="USD">1,644,884</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_204" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitref="USD">198,869</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net change in cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_205" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitref="USD">119,096</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_206" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" unitref="USD">12,868</ix:nonfraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect from foreign currency exchange</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_207" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitref="USD">754</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_208" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitref="USD">-</ix:nonfraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash and cash equivalents at beginning of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_209" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">1,751,499</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2020-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_210" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">22,245</ix:nonfraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash and cash equivalents at end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_211" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">1,871,349</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="AsOf2021-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_212" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitref="USD">9,377</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental disclosures of noncash financing and investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Issuance of convertible notes for payables - related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_214" name="aimd:IssuanceOfConvertibleNotesForPayablesRelatedParty" unitref="USD">26,000,000</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_215" name="aimd:IssuanceOfConvertibleNotesForPayablesRelatedParty" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Receivable of convertible notes issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_216" name="us-gaap:NotesIssued1" unitref="USD">50,000</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_217" name="us-gaap:NotesIssued1" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net change in equipment payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_218" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitref="USD">202,002</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-03-31" decimals="0" format="ixt:zerodash" id="fid_219" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" unitref="USD">-</ix:nonfraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to condensed consolidated financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong> Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="note" style="display: inline">Notes to Financial Statements </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_220" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. </strong><strong>Organization and Business.</strong> Ainos, Inc., a Texas corporation formerly known as Amarillo Biosciences, Inc. (the "Company", "we" or "us"), is engaged in developing medical technologies for point-of-care (“POCT”) testing and safe and novel medical treatment for a broad range of disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and clinical development activities for our programs, securing related intellectual property and commercialization of proprietary therapeutics using low-dose non-injectable interferon (“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products. Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the commercialization of medical devices as part of our diversification strategy. Since the beginning of 2021, we have acquired significant intellectual property from our majority shareholder, Ainos, Inc., a Cayman Islands corporation (“Ainos KY”), to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) POCTs and COVID-19 POCTs. We expect our underlying intellectual property to enable us to expedite the commercialization of our medical device pipeline, beginning with the Ainos-branded COVID-19 POCT product candidates.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_226" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. </strong><strong>Basis of presentation.</strong> The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K/A for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on April 15, 2022  have been prepared in accordance with the Generally Accepted Accounting Principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by for audited financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2022.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" continuedat="cont_512b30" escape="true" id="fid_221" name="aimd:FinancialConditionTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. </strong><strong>Financial Condition.</strong> These financial statements have been prepared in accordance with GAAP, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved sustained operating income, and its operations are funded primarily from related-party convertible debt and equity financings. However, losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_512b30"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that capital will be available as necessary to meet the Company’s working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company’s liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_222" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. </strong><strong>Common Stock.</strong> We have <ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_241" name="aimd:CommonStockAuthorized" unitref="Shares">300,000,000</ix:nonfraction> shares of voting common shares authorized for issuance. On March 31, 2022, a total of <ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_245" name="us-gaap:CommonStockSharesIssued" unitref="Shares">163,987,550</ix:nonfraction> shares of common stock were either issued (<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_235" name="aimd:ReservedForConversionOfConvertibleDebtToStock" unitref="Shares">144,379,308</ix:nonfraction>), reserved for conversion of convertible debt to stock (<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_238" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitref="Shares">17,285,625</ix:nonfraction>), reserved for future issuance of RSUs for non-employee directors (<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="-6" format="ixt:numdotdecimal" id="fid_277" name="aimd:RestrictedShare" scale="6" unitref="Shares">1,320,000</ix:nonfraction>), held for future exercise of stock options (<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_236" name="aimd:FutureExerciseOfStockOptions" unitref="Shares">550,000</ix:nonfraction>) and shares reserved for warrant conversion (<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="0" format="ixt:numdotdecimal" id="fid_237" name="aimd:SharesReservedForWarrantConversion" unitref="Shares">452,617</ix:nonfraction>). We also have $<ix:nonfraction contextref="AsOf2022-03-31_aimd_CommonStocksMember" decimals="-5" format="ixt:numdotdecimal" id="fid_234" name="aimd:CommonStockSharesOutstandingAndReserved" scale="6" unitref="Shares">26.9</ix:nonfraction> million outstanding in convertibles notes which are convertible into shares of common stock upon and at a conversion price equal to 80% of the offering price of any public offering as a result of which the Company's common stock is listed on a national exchange.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_223" name="us-gaap:PreferredStockTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. </strong><strong>Preferred Stock</strong>. We have <ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_271" name="us-gaap:PreferredStockSharesAuthorized" unitref="Shares">10,000,000</ix:nonfraction> shares of preferred stock authorized for issuance. No shares of preferred stock were outstanding as of March 31, 2022.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" continuedat="cont_a5dde2" escape="true" id="fid_229" name="us-gaap:DebtDisclosureTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. </strong><strong>Current Convertible Notes Payable and Other Notes Payable.</strong> As of March 31, 2022 and December 31, 2021, the amount of convertible and other notes payable totaled $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_815" name="us-gaap:DebtConversionOriginalDebtAmount1" unitref="USD">4,389,931</ix:nonfraction> and $<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_816" name="us-gaap:DebtConversionOriginalDebtAmount1" unitref="USD">3,589,931</ix:nonfraction>, respectively. The details of the convertible notes payable and other notes payable are shown in the table below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_233" name="us-gaap:ConvertibleDebtTableTextBlock"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:5%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No.</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Due Date</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>From Effective</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Following Maturity</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Conversion Rate</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issuing Purpose</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of 12/31/2021</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Addition</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payment</strong></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of 3/31/2022</strong></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accrued Interest</strong></p></td></tr><tr style="height:15px"><td colspan="14" style="width:89%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Current Convertible Notes Payable:</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#1.16</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" id="fid_440" name="aimd:EffectiveDate">1/30/2016</ix:nonnumeric></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" id="fid_384" name="aimd:DueDate">Payable on demand</ix:nonnumeric></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" decimals="INF" id="fid_412" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">0.75</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" decimals="INF" format="ixt:numdotdecimal" id="fid_510" name="aimd:ConversionRate" unitref="USDPShares">0.17</ix:nonfraction> </p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_468" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">114,026</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:zerodash" id="fid_357" name="aimd:TotalConvertibleAndNonconvertiblepayment" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember" decimals="0" format="ixt:zerodash" id="fid_534" name="aimd:DebtInstrumentPayment" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_469" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">114,026</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_359" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">6,050</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#2.16</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" id="fid_441" name="aimd:EffectiveDate">3/18/2016</ix:nonnumeric></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" id="fid_385" name="aimd:DueDate">Payable on demand</ix:nonnumeric></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" decimals="INF" id="fid_413" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">0.65</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" decimals="INF" format="ixt:numdotdecimal" id="fid_511" name="aimd:ConversionRate" unitref="USDPShares">0.19</ix:nonfraction> </p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_470" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">262,500</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TotalMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_535" name="aimd:DebtInstrumentPayment" unitref="USD">-</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="0" format="ixt:zerodash" id="fid_540" name="aimd:DebtInstrumentPayment" unitref="USD">-</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_471" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">262,500</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" decimals="0" format="ixt:numdotdecimal" id="fid_360" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">10,298</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"></td><td style="width:5%;"></td><td style="width:7%;"></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:6%;"></td><td style="width:8%;"></td><td style="width:7%;"></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_DrStephenTChenMember" decimals="0" format="ixt:numdotdecimal" id="fid_482" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">376,526</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember" decimals="0" format="ixt:zerodash" id="fid_557" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_558" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_DrStephenTChenMember" decimals="0" format="ixt:numdotdecimal" id="fid_483" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">376,526</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_DrStephenTChenMember" decimals="0" format="ixt:numdotdecimal" id="fid_361" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">16,348</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#12.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" id="fid_448" name="aimd:EffectiveDate">4/27/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" id="fid_392" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_420" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_517" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_484" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">15,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_559" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_560" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_602" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">15,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwelveTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_362" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">257</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#13.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" id="fid_449" name="aimd:EffectiveDate">5/5/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" id="fid_393" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_421" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_518" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_485" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">20,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_561" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_562" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_603" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">20,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_ThirteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_363" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">335</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#14.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" id="fid_450" name="aimd:EffectiveDate">5/25/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" id="fid_394" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_422" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_519" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_486" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">30,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_563" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_564" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_604" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">30,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_FourteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_364" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">471</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#15.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" id="fid_451" name="aimd:EffectiveDate">5/28/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" id="fid_395" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_423" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_520" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_487" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">35,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_565" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_566" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_605" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">35,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_FifteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_365" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">545</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#16.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" id="fid_452" name="aimd:EffectiveDate">6/9/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" id="fid_396" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_424" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_521" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_488" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_567" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_568" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_492" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_366" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">4,486</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#17.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" id="fid_453" name="aimd:EffectiveDate">6/21/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" id="fid_397" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_425" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_509" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_489" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">107,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_569" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_570" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_607" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">107,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_SeventeenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_367" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">1,535</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#18.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" id="fid_454" name="aimd:EffectiveDate">7/2/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" id="fid_398" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_426" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_522" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_490" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">54,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TotalMember_aimd_AinosKYMember" decimals="0" format="ixt:zerodash" id="fid_571" name="aimd:AdditionInDebtinstrument" unitref="USD">-</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_608" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">54,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_368" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">744</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#19.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" id="fid_455" name="aimd:EffectiveDate">9/1/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" id="fid_399" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_427" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_523" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_491" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">120,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_609" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">120,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_369" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">1,289</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#20.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" id="fid_456" name="aimd:EffectiveDate">9/28/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" id="fid_611" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="INF" id="fid_610" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_524" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_495" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_SixteenTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_606" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_370" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">2,798</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#21.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" id="fid_457" name="aimd:EffectiveDate">11/10/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" id="fid_613" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="INF" id="fid_612" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_525" name="aimd:ConversionRate" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_493" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">50,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_621" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">50,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwentyTwentyOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_371" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">357</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#22.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" id="fid_458" name="aimd:EffectiveDate">11/25/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" id="fid_615" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="INF" id="fid_614" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_EighteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_575" name="aimd:ConversionNote" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_494" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">450,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_622" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">450,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwentyTwoTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_372" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">2,851</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#23.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" id="fid_459" name="aimd:EffectiveDate">11/29/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" id="fid_617" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="INF" id="fid_616" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_NinteenTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_576" name="aimd:ConversionNote" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_620" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_623" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">300,000</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwentyThreeMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_373" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">1,840</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#24.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" id="fid_460" name="aimd:EffectiveDate">12/29/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" id="fid_619" name="aimd:DueDate">2/28/2023</ix:nonnumeric> (1) </p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="INF" id="fid_618" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$ <ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyTwoOneMember_aimd_AinosKYMember" decimals="INF" format="ixt:numdotdecimal" id="fid_577" name="aimd:ConversionNote" unitref="USDPShares">0.20</ix:nonfraction></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_496" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">1,219,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_624" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">1,219,000</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TwentyFourTwoMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_374" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">5,684</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p></td><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TotalMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_497" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">3,000,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TotalMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_498" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">3,000,000</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TotalMember_aimd_AinosKYMember" decimals="0" format="ixt:numdotdecimal" id="fid_375" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">23,192</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="8" style="width:55%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> Total convertible notes payable- related parties</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_579" name="aimd:Convertibleandothernotespayablerelatedparties" unitref="USD">3,376,526</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_580" name="aimd:Convertibleandothernotespayablerelatedparties" unitref="USD">3,376,526</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_581" name="aimd:RelatedPartyAccruedliabilitiescurrent" unitref="USD">39,540</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="3" style="width:19%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Non-Convertible Notes Payable:</strong></p></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:6%;"></td><td style="width:8%;"></td><td style="width:7%;"></td><td style="width:7%;"></td><td style="width:6%;"></td><td style="width:6%;"></td><td style="width:7%;"></td><td colspan="2" style="width:7%;"></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#9.21</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" id="fid_409" name="aimd:DueDate">1/1/2021</ix:nonnumeric></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" id="fid_408" name="aimd:DueDate">4/14/2021</ix:nonnumeric></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="INF" id="fid_436" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">0.13</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="0" format="ixt:numdotdecimal" id="fid_504" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">129,405</ix:nonfraction></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_585" name="aimd:NonConvertibleNotesPayableRelatedParty" unitref="USD">129,405</ix:nonfraction></p></td><td colspan="2" style="width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="0" format="ixt:numdotdecimal" id="fid_377" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">354</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#26.22 (2)</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" id="fid_630" name="aimd:EffectiveDate">3/4/2022</ix:nonnumeric></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" id="fid_632" name="aimd:DueDate">3/31/2023</ix:nonnumeric></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" decimals="INF" id="fid_631" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" decimals="0" format="ixt:numdotdecimal" id="fid_634" name="aimd:AdditionInDebtinstrument" unitref="USD">800,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" decimals="0" format="ixt:numdotdecimal" id="fid_628" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">800,000</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_AinosKYMember_aimd_TwentySixTwoTwoMember" decimals="0" format="ixt:numdotdecimal" id="fid_633" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">1,135</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;"></td><td style="width:5%;"></td><td style="width:7%;"></td><td colspan="5" style="width:36%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Non-convertible notes payable-related party </p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" decimals="0" format="ixt:numdotdecimal" id="fid_625" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">129,405</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_637" name="aimd:NonConvertibleNotesPayableRelatedPartyAddition" unitref="USD">800,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_635" name="aimd:NonConvertibleNotesPayableRelatedParty" unitref="USD">929,405</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_636" name="aimd:NonConvertibleNotesPayableRelatedPartyAccruedInterest" unitref="USD">1,489</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2 China</p></td><td style="width:5%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#8b.20</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" id="fid_465" name="aimd:EffectiveDate">1/1/2020</ix:nonnumeric></p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonnumeric contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_NineTwoOneMember" id="fid_464" name="aimd:EffectiveDate">1/1/2021</ix:nonnumeric></p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" decimals="INF" id="fid_437" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" scale="-2" unitref="Pure">1.85</ix:nonfraction>%</p></td><td style="width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">N/A</p></td><td style="width:7%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_502" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">84,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_503" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitref="USD">84,000</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" decimals="0" format="ixt:numdotdecimal" id="fid_376" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">3,527</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="5" style="width:36%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Non-Convertible Notes payable- non-related party</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" decimals="0" format="ixt:numdotdecimal" id="fid_626" name="aimd:ConsultingFee" unitref="USD">84,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" decimals="0" format="ixt:numdotdecimal" id="fid_627" name="aimd:ConsultingFee" unitref="USD">84,000</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" decimals="0" format="ixt:numdotdecimal" id="fid_379" name="us-gaap:AccruedLiabilitiesCurrent" unitref="USD">3,527</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="5" style="width:36%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total non-convertible notes payable</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_639" name="aimd:TotalNonConvertibleNotesPayable" unitref="USD">213,405</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_641" name="aimd:TotalNonConvertibleNotesPayableAddition" unitref="USD">800,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_638" name="aimd:TotalNonConvertibleNotesPayable" unitref="USD">1,013,405</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_640" name="aimd:TotalNonConvertibleNotesPayableAccruedInterest" unitref="USD">5,016</ix:nonfraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:6%;"></td><td style="width:5%;"></td><td colspan="6" style="width:43%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total convertible and non-convertible</p></td><td style="BORDER-BOTTOM: 3px double;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_354" name="aimd:TotalConvertibleAndNonconvertible" unitref="USD">3,589,931</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_356" name="aimd:TotalConvertibleAndNonconvertibleaddition" unitref="USD">800,000</ix:nonfraction></p></td><td style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">-</p></td><td style="BORDER-BOTTOM: 3px double;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_355" name="aimd:TotalConvertibleAndNonconvertible" unitref="USD">4,389,931</ix:nonfraction></p></td><td colspan="2" style="BORDER-BOTTOM: 3px double;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_358" name="aimd:TotalConvertibleAndNonconvertiblepaymentaccrued" unitref="USD">44,556</ix:nonfraction></p></td></tr></tbody></table></ix:nonnumeric></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_a5dde2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(1) On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023. The total unpaid principal for these extended period convertible notes amount to $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_809" name="aimd:ConvertibleNotesAmount" unitref="USD">3,000,000</ix:nonfraction> in the aggregate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(2) On March 11, 2022, the Board approved a Non-Convertible Note dated March 4, 2022 in favor of Ainos KY with a principal amount of $<ix:nonfraction contextref="From2022-03-01to2022-03-11" decimals="0" format="ixt:numdotdecimal" id="fid_810" name="aimd:PrincipalAmountProperty" unitref="USD">800,000</ix:nonfraction>, interest of 1.85% per annum on unpaid principal and accrued interest, and a maturity date of February 28, 2023. The Note includes standard provisions for notice, default, and remedies for default.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All of the aforementioned convertible promissory notes and other notes payable are unsecured and due on demand upon maturity. The Company may prepay the notes in whole or in part at any time. The holder of convertible notes has the option to convert some or all of the unpaid principal and accrued interest to our common voting stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The total interest expense of convertible notes payable and other notes payable for the three months ended March 31, 2022 and as of December 31 2021 was $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_813" name="us-gaap:InterestExpense" unitref="USD">15,883</ix:nonfraction> and $<ix:nonfraction contextref="From2021-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_814" name="us-gaap:InterestExpense" unitref="USD">11,897</ix:nonfraction> respectively; the cumulative related accrued interest as of March 31, 2022 and December 31, 2021 were $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_811" name="aimd:CumulativeAccruedInterest" unitref="USD">44,556</ix:nonfraction> and $<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_812" name="aimd:CumulativeAccruedInterest" unitref="USD">28,673</ix:nonfraction>, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" continuedat="cont_d6644e" escape="true" id="fid_230" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. </strong><strong>Non-Current Convertible Notes Payable. </strong>As of March 31, 2022 and December 31, 2021, the amount of non-current convertible notes payable was $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_295" name="aimd:NonCurrentConvertibleNotesPayable" unitref="USD">26,900,000</ix:nonfraction> and $<ix:nonfraction contextref="From2020-01-01to2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_296" name="aimd:NonCurrentConvertibleNotesPayable" unitref="USD">0</ix:nonfraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 30, 2022, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_304" name="us-gaap:ConvertibleNotesPayable" unitref="USD">26,000,000</ix:nonfraction> (the “APA Convertible Note”) for the Asset Purchase Transaction as more particularly described below in Item 8 in these Notes to Financial Statements. The principal sum of the APA Convertible Note is payable in cash on January 30, 2027, although we may prepay the APA Convertible Note in whole or in part without penalty. The APA Convertible Note is noninterest bearing. If not earlier repaid, the APA Convertible Note will be converted into shares of our common stock or such other securities or property for which the APA Convertible Note may become convertible, immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be 80% of the initial public offering price of the offering.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_d6644e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">Convertible Note Offering Pursuant to Regulation S</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company issued Convertible Notes pursuant to certain Convertible Note Purchase Agreements under Regulation S. The transactions are more particularly described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">$<ix:nonfraction contextref="AsOf2022-03-31_aimd_YunHanLiaoMember" decimals="0" format="ixt:numdotdecimal" id="fid_817" name="aimd:ConvertibleNoteIssued" unitref="USD">50,000</ix:nonfraction> Convertible Note issued on March 31, 2022 to Yun-Han Liao. The purchaser is the daughter of Wu Hui-Lan, the Company’s Chief Financial Officer (the “Liao Convertible Note”).</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">$<ix:nonfraction contextref="AsOf2022-03-28_aimd_ChihHengTsaiMember" decimals="0" format="ixt:numdotdecimal" id="fid_821" name="aimd:ConvertibleNoteIssued" unitref="USD">850,000</ix:nonfraction> aggregate Convertible Notes issues on March 28, 2022 to Chih-Cheng Tsai, Ming-Hsien Lee, Yu-Yuan Hsu, and Top Calibre Corporation, a British Virgin Islands company (collectively the “Regulation S Notes”).</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">The Liao Convertible Note and the Regulation S Notes are collectively referred to as the “Convertible Notes”.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Principal Amount of the Convertible Notes are payable in cash on March 30, 2027, although the Company may prepay the Convertible Notes in whole or in part without penalty. The Convertible Notes are non-interest bearing. If not earlier repaid, the Convertible Notes will be converted into shares of common stock, $<ix:nonfraction contextref="AsOf2022-03-31" decimals="INF" format="ixt:numdotdecimal" id="fid_300" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitref="USDPShares">0.01</ix:nonfraction> par value per share of the Company, or such other securities or property for which the Convertible Notes may become convertible, immediately prior to the closing of any public offering of the Company’s common stock as result of which the Company’s common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be eighty percent (80%) of the initial public offering price of the offering.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" continuedat="cont_296c70" escape="true" id="fid_224" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. </strong><strong>Related Party Transactions.</strong> The following is a summary of related party transactions that met our disclosure threshold for the three months ended March 31, 2022 and 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Asset Purchase Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY and the Company entered into an Asset Purchase Agreement dated as of November 18, 2021(the “Asset Purchase Agreement”), as modified by an Amended and Restated Asset Purchase Agreement dated as of January 29, 2022 (the “Amended Asset Purchase Agreement”). Pursuant to the Asset Purchase Agreement, the Company acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_326" name="us-gaap:DueToRelatedPartiesCurrent" unitref="USD">26,000,000</ix:nonfraction>. Pursuant to the Asset Purchase Agreement, the Company agreed to hire certain employees of Ainos KY who are responsible for research and development of the IP Assets and/or Equipment on terms at least equal to the compensation arrangements undertaken by Ainos KY. From and after the closing, we will have no responsibility, duty or liability with respect to any employee benefit plans of Ainos KY. As payment of the purchase price, we issued to Ainos KY a Convertible Promissory Note in the principal amount of $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_323" name="aimd:PrincipalAmountProperty" unitref="USD">26,000,000</ix:nonfraction> upon closing on January 30, 2022 (the “APA Convertible Note”). Refer to Note 7 of the Notes to Financial Statements for more information.</p></ix:nonnumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:continuation id="cont_296c70"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Related Party Working Capital</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All convertible and other notes payable were issued either as a result of financing or deferred compensation provided by related parties. As of March 31, 2022 and December 31, 2021, the convertible and non-convertible notes payable for related parties totaled $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_316" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" unitref="USD">4,355,931</ix:nonfraction> and $<ix:nonfraction contextref="AsOf2021-12-31" decimals="0" format="ixt:numdotdecimal" id="fid_317" name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" unitref="USD">3,505,931</ix:nonfraction>, respectively. Refer to Note 6 and 7 of the Notes to Financial Statements for more information.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Purchase related to COVID-19 Antigen Rapid Test Kits</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We incurred costs associated with finished goods, raw materials and manufacturing fees for Covid-19 antigen rapid test kits from TCNT pursuant to a Sales and Marketing Agreement, totaling $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_321" name="aimd:CovidNinteenAntigenRapidTestKitsAmount" unitref="USD">386,412</ix:nonfraction> for the three months ended March 31, 2022. There were no purchases from TCNT during the same period last year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Product Co-development Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the five-year product co-development agreement effective on August 1, 2021 with TCNT (the “Product Co-Development Agreement”) we incurred development expenses totaling $<ix:nonfraction contextref="From2022-01-01to2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_327" name="aimd:ResearchAndDevelopmentExpense1" unitref="USD">167,422</ix:nonfraction> for the three months ended March 31, 2022 of which $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_328" name="us-gaap:AccountsPayableCurrent" unitref="USD">109,131</ix:nonfraction> is in accrued payable as of March 31, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Promissory Note Extension Agreement</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 17, 2022, we executed a Promissory Note Extension Agreement with Ainos KY in which the due dates for certain convertible notes enumerated as #12.21 to #24.21 issued by the Company to Ainos KY were extended to February 28, 2023 (the “Promissory Note Extension Agreement”). The total unpaid principal for these extended period convertible notes amount to $<ix:nonfraction contextref="AsOf2022-03-31" decimals="0" format="ixt:numdotdecimal" id="fid_329" name="aimd:ConvertibleNotesAmount" unitref="USD">3,000,000</ix:nonfraction> in the aggregate. Refer to Footnote 1 of Note 6 of the Notes to Financial Statements for more information. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><ix:nonnumeric contextref="From2022-01-01to2022-03-31" escape="true" id="fid_225" name="us-gaap:SubsequentEventsTextBlock"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. </strong><strong>Subsequent Events. </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 11, 2022, we issued to ASE Test Inc., a minority owner of Ainos KY, a convertible note in the principal amount of $<ix:nonfraction contextref="AsOf2027-03-30_us-gaap_SubsequentEventMember" decimals="0" format="ixt:numdotdecimal" id="fid_343" name="us-gaap:ConvertibleNotesPayable" unitref="USD">500,000</ix:nonfraction> due on March 30, 2027 (the “ASE Note”). The convertible note will automatically convert into shares of our common stock immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be <ix:nonfraction contextref="AsOf2027-03-30_us-gaap_SubsequentEventMember" decimals="INF" id="fid_337" name="aimd:InitialPublicOfferingPriceOfTheOfferingPercentage" scale="-2" unitref="Pure">80</ix:nonfraction>% of the initial public offering price of the offering. </p></ix:nonnumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">   </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i2" style="display: inline">ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Some of the statements in this report are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “foresee,” “may,” “guidance,” “estimate,” “potential,” “outlook,” “target,” “forecast,” “likely” or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data, or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">the extent and duration of the COVID-19 pandemic and the impact of the end of the COVID-19 pandemic on our business and our expectations regarding customer and user demand for our COVID-19 test;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">possible changes in capital structure, financial condition, future working capital needs and other financial items;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">our expectations of the reliability, accuracy and performance of our products and services; </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">our ability to obtain additional funds for our operations;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">unforeseen changes in the course of research and development activities and in clinical trials;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our ability to obtain and maintain regulatory authorizations, clearances or approvals for our tests and other product candidates, including EUAs (“Emergency Use Authorizations”) for our COVID-19 test or other product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our ability to successfully build out our sales and marketing infrastructure, the costs and success of our marketing efforts, and our ability to promote our brand;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our ability to establish demand for our products and services and expand geographically;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our intellectual property position and our expectations regarding our ability to obtain and maintain intellectual property protection;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our ability to effectively manage our expected growth, including our ability to retain and recruit personnel, and maintain our culture;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">possible changes in cost, timing and progress of development, preclinical studies, clinical trials and regulatory submissions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">the rate and degree of market acceptance of any approved product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">the impact of applicable U.S., Taiwanese and international laws and regulations; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">our ability to implement, maintain and improve effective internal controls and remediate material weaknesses.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any forward-looking statements in this report are made only as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained in this report to reflect subsequent events or circumstances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Ainos, Inc., a Texas corporation formerly known as Amarillo Biosciences, Inc. (the "Company", "we" or "us"), is engaged in developing medical technologies for point-of-care (“POCT”) testing and safe and novel medical treatment for a broad range of disease indications. Since our inception in 1984, we have concentrated our resources on business planning, raising capital, research and clinical development activities for our programs, securing related intellectual property and commercialization of proprietary therapeutics using low-dose non-injectable interferon (“IFN”). In addition to our core IFN technology, we are committed to developing a diversified healthcare business portfolio to include medical devices and consumer healthcare products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Although we have historically been involved in extensive pharmaceutical research and development of low-dose oral interferon as a therapeutic, we are prioritizing the commercialization of medical devices as part of our diversification strategy. Since the beginning of 2021, we have acquired significant intellectual property from our majority shareholder, Ainos, Inc., a Cayman Islands corporation (“Ainos KY”), to expand our potential product portfolio into Volatile Organic Compounds (“VOC”) and COVID-19 POCTs. We expect our underlying intellectual property to enable us to expedite the commercialization of our medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Our portfolio of products</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our portfolio of products is currently comprised of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>COVID-19 Antigen Rapid Test Kit and Ainos’ Cloud-based Test Management Apps</strong>. Our cloud-based test management platform is comprised of an antigen rapid test kit, a personal application, or app, and an enterprise app. We anticipate our management apps will allow individuals and organizations to seamlessly manage tests, trace infections, and share results. As the first commercialized COVID-19 product we sell, we currently market the Ainos COVID-19 antigen rapid test kit in Taiwan under emergency use authorization (“EUA”) issued by the Taiwan Federal and Drug Administration (“TFDA”) in 2021. We market the Ainos COVID-19 antigen rapid test kit under our brand name. The kit is manufactured by TCNT, our product co-developer.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>COVID-19 Nucleic Acid Test</strong>. Our solution consists of a color-changing assay that is compatible with standard Polymerase Chain Reaction (“PCR”) machines and delivers test results within 40 minutes. In addition to our assay’s compatibility with existing PCR equipment, we will also offer portable, low-cost test equipment intended to help medical professionals quickly scale testing capacity. We will market the product under the Ainos brand name, and our co-developer TCNT will manufacture the product.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>VOC POCT </strong><strong>–</strong><strong> Ainos Flora</strong>. Our Ainos Flora device will perform a non-invasive test for female vaginal health and certain sexually transmitted diseases (“STDs”) including vaginitis, gonorrhea and trichomoniasis, within a few minutes. We expect Ainos Flora will provide convenient, discreet, rapid testing in a point-of-care setting which will allow women to self-test at home.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>VOC POCT </strong><strong>–</strong><strong> Ainos Pen</strong>. Our Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions including oral, gastrointestinal, liver, and renal health within minutes. We expect consumers to be empowered to share their self-test results with their physicians through in-person and telehealth medical consultations.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>VOC POCT </strong><strong>–</strong><strong> CHS430</strong>. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia within 10 minutes, as compared to current standard of care invasive culture tests that typically take more than two days to provide results. We plan to be the exclusive sales agent for CHS430, pursuant to our Product Development Agreement with our co-developer, TCNT, who will manufacture the product.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>Very Low-Dose Oral Interferon Alpha (</strong><strong>“</strong><strong>VELDONA</strong><strong>”</strong><strong>)</strong>. VELDONA is a low-dose oral interferon alpha (“IFN-α”) formulation based on our nearly four decades of research on IFN-α’s broad treatment applications. We recently initiated a strategic relationship with InnoPharmax, Inc. to jointly develop and market an orally administered cytotoxin-induced complementary combined therapy (“CICCT”) for the treatment of COVID-19 and other potential viral infections. We are conducting a parallel study for the COVID-19 treatment based on VELDONA alone.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><strong>Synthetic RNA (</strong><strong>“</strong><strong>SRNA</strong><strong>”</strong><strong>)</strong>. We are developing a SRNA technology platform in Taiwan. Our initial focus is to develop a potential COVID-19 mRNA vaccine platform using the full-length spike or the RBD gene sequence of the alpha and delta variants as reference sequences.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">An integral part of our operating strategy is to create multiple revenue streams through commercializing our product portfolio and leveraging our intellectual property patents, including potentially out-licensing or forming strategic relationships to develop our medical devices, consumer healthcare products and low-dose interferon therapeutics. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In 2022, we are prioritizing the commercialization of our POCT devices, beginning with seeking EUA authorizations for the COVID-19 POCT product candidates and plans to commercialize our other POCT product candidates. As a general strategy, we plan to conduct clinical trials in Taiwan and use the data to apply for TFDA approval and FDA clearance via the 510(k) or comparable pathway. If our products are approved, we plan to work with third-party distributors to market our products in countries where we receive regulatory approval and to seek various business relationships with other medtech companies to market our products. At the same time, we plan to initiate clinical trials for the CICCT and SRNA programs over the course of this year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our ability to generate product revenue sufficient to achieve profitability will depend on further successful development and commercialization of one or more of our current or future product candidates and programs. We anticipate our POCT products candidates to potentially generate organic cash flows to support our business while we invest in our other pipeline projects. We expect to continue to incur significant expenses for the next few years as we advance our product candidates through preclinical development, clinical trials and regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution, and legal and regulatory compliance. We may also incur expenses in connection with strategic relationships for the development of additional product candidates. Furthermore, we expect to continue to incur costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Until we can generate significant revenue from product sales, if ever, we expect to finance our operations with business revenues and proceeds from external sources. We may pursue additional funding that may include our entry into or expansion of borrowing arrangements; research and development incentive payments, government grants, co-financing from pharmaceutical companies and other corporate sources; and potential future collaboration agreements with pharmaceutical companies or other third parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization, potential in-licenses or acquisitions plans for one or more of our product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We are unable to predict the timing or amount of unexpected expenses or when or if we will be able to achieve or maintain profitability due to the numerous risks and uncertainties associated with product development and related legal regulatory requirements. When we are eventually able to generate additional product sales, those sales may not be sufficient to become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">As of March 31, 2022, we had available cash and cash equivalents of $1,871,349. We anticipate business revenues and further potential financial support from external sources to fund our operations over the next twelve months. We have based this estimate on assumptions that may prove to be incorrect and we could exhaust our available capital resources sooner than we expect. See ”Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources” for additional information. To finance our continuing operations, we will need to raise additional capital, which cannot be assured.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Impact of COVID-19 on Our Business </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The COVID-19 pandemic presented us an opportunity to grow our business. Substantially all of our operating revenue came from the sale of the Ainos COVID-19 antigen rapid test kits in Taiwan. We intend to broaden our market reach if TCNT, our product co-developer and manufacturing partner, successfully obtains regulatory clearance in the U.S. or other countries. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We believe affordable, easy-to-use, rapid COVID-19 testing will continue to be in demand at least in the short-term. We anticipate our management apps, when used with the Ainos antigen rapid test kit, will allow individuals and organizations to effectively manage tests, trace infections, and share results. We also anticipate the Ainos COVID-19 nucleic acid test can help medical professionals quickly scale testing capacity if the product receives regulatory clearance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">We are continuing to monitor the potential impact of the pandemic, but we cannot be certain the future impact on our business, financial condition, results of operations and prospects. Depending on developments relating to the pandemic, including the emergence of new variants, the pandemic may affect our ability to initiate and complete research studies, delay the initiation of our future research studies, disrupt regulatory activities or have other adverse effects on our business, results of operations, financial condition and prospects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Results of Operations for Quarter Ended March 31, 2022 (“Q1 2022”) and March 31, 2021 (“Q1 2021”):</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Revenues.</strong> The Company reported $87,200 in revenue in Q1 2022 from product sales of the Ainos COVID-19 Antigen Rapid Test Kits. Revenue from product sales in Q1 2021 was $2,121 generated from sales of liposomal nutraceuticals. The cost of sales relating to product sales in Q1 2022 was $41,078 compared to $1,249 in Q1 2021. Gross profit from product sales in Q1 2022 was $46,122 as compared to $872 in Q1 2021. Gross profits generated from product sales increased by $45,250 between Q1 2022 and the same quarter in the previous year. In 2021, the Company discontinued sales of liposomal nutraceuticals and instead plans to focus on sales of POCTs, including the Ainos COVID-19 Antigen Test Kit. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Research and Development Expenses.</strong> R&amp;D expenses in Q1 2022 were $1,577,454 mainly consisting of amortization expense of intellectual property assets, staffing and co-development research. There were no R&amp;D expenses during the same quarter in 2021. We expect that our R&amp;D expenses will increase over time as we further product development of our POCT and other product candidates. In addition to increasing our in-house R&amp;D staffing, we also contribute R&amp;D funding under our co-development agreements with Taiwan Carbon Nano Technology (“TCNT”), our manufacturing collaborator and our affiliate company, for POCT products and InnoPharmax, Inc. to jointly develop and promote an orally administered CICCT for the treatment of COVID-19 and potentially other viral infections.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Selling, General and Administrative Expenses.</strong> Selling, general and administrative expenses were $551,730 and $522,981 in Q1 2022 and Q1 2021, respectively. The $28,749 (6%) increase was largely due to increased expenses associated with staffing and consulting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Operating Loss.</strong> The Company's operating loss was $2,083,062 and $522,109 in Q1 2022 and Q1 2021, respectively, reflecting a $1,560,953 (299%) increase in operating losses between the reporting periods. As stated in our discussion about R&amp;D expenses, our operating losses are mainly attributable to additional R&amp;D expenses in line with the Company's product development initiatives. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Interest Expense.</strong> In Q1 2022 interest expense was $16,687 compared to $11,897 in Q1 2021, due to accrued interest for convertible and other debt notes issued by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Net Loss. </strong>Net loss attributable to common stock shareholders was $2,099,895, in Q1 2022 compared to $534,006 in Q1 2021, resulting in a $1,565,889 (293%) increase in net losses attributable to our shareholder of common stock. The net losses are attributable to increased R&amp;D expenses in line with the Company's product development plans. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>Liquidity and Capital Resources</strong><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">As of March 31, 2022 and December 31, 2021, the Company had available cash of $1,871,349 and $1,751,499, respectively. The following table summarizes our cash flows for the first quarter of 2022:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.95pt; text-align:center;"><strong>Three Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,389,889</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(211,737</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(135,899</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,644,884</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198,869</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>Operating activities:</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash used in operating activities increased in Q1 2022 compared to Q1 of 2021, due to higher net loss and negative working capital.  We incurred net operating outflow of $1,389,889 for Q1 2022 and $211,737 for Q1 2021. While our revenues grew in Q1 2022 due to sales of the Ainos COVID-19 test kits, our acquisition of intellectual property and equipment, increased staffing, and investment in research and developments increased our expenses and resulted in higher net losses of $2,099,895. These higher net losses were partially offset by increased amortization and depreciation for acquisition of intellectual property and equipment to $1,168,773 for Q1 2022 from $3,905 for Q1 2021. Negative working capital primarily resulted from the increase of inventories due to upcoming anticipated sales activities and the increase of other current assets primarily due to the preparation for a potential public offering for which we filed a Registration Statement on Form S-1 under the Securities Act of 1944, as amended, on April 28, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Investing activities:</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash used in investing activities increased in Q1 2022 compared to cash used in Q1 2021, driven by the acquisition of R&amp;D equipment, and building out existing facilities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Financing activities:</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash provided by financing activities increased in Q1 2022 compared to cash provided in Q1 2021, which primarily reflects higher proceeds from convertible notes payable and notes payable.  For a discussion of the notes, see “Part II, Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds.”</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of March 31, 2022, the principal amount of our convertible and other notes payable due within the next 12 months was $3,376,526 and $1,013,405, respectively. The holders of these notes waived their rights to the unpaid default interest under the notes in Q3 2021. See footnotes 4 and 6 of consolidated financial statements for more information related to convertible and other notes payable. In March 2022, we issued a non-convertible note in the principal amount of $800,000 due in March 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 30, 2022, we issued a noninterest-bearing Convertible Promissory Note in the principal amount of $26,000,000 (the “APA Convertible Note”) in connection with the closing under the Asset Purchase Agreement. The  principal amount of the APA Convertible Note is due in January 2027. If not earlier repaid, the APA Convertible Note will be converted into shares of our common stock immediately prior to the closing of any public offering of our common stock as a result of which our common stock will be listed on a U.S. stock exchange.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, in the first quarter of 2022, we executed $900,000 of convertible notes with terms that are substantially similar to the terms of the APA Convertible Note.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2022 we intend to focus on commercializing our POCT medical devices and developing our CICCT program. Our near-term liquidity requirements will include expenses for clinical trials, repayment of debt not converted into equity, regulatory clearances, and marketing to commercialize our POCT devices, including the Ainos COVID-19 Nucleic Acid Test, the Ainos Flora, the Ainos Pen and our CICCT program. We also intend to increase staffing for general administration, marketing and technology development purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In 2023 and beyond, we intend to invest in research and development and clinical trial spending to advance our VELDONA development efforts for disease indications such as thrombocytopenia and Sjögren’s syndrome. We also plan on investing in clinical trials and regulatory approval for the CHS430 device, in collaboration with TCNT, and clinical trial expenses for our SRNA program.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company anticipates that its cash reserves, business revenues from the Ainos COVID-19 test kits, sales of its common stock, and debt financing through convertible and non-convertible notes are sufficient to fund the Company’s operations over the next twelve months. As the number of reported COVID cases has been increasing in Taiwan, we anticipate demand for the test kits to increase, at least in the short term.  There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan, including, as required, additional external financing from our majority shareholder. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i3" style="display: inline">ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">As a “smaller reporting company,” we are not required to provide the information under this Item 3.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i4" style="display: inline">ITEM 4. Controls and Procedures</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em>Internal Control Over Financial Reporting</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). As previously disclosed in our Form 10-K/A for the year ended December 31, 2021, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021. As a result of such review as of December 31, 2021, we identified certain deficiencies in the design and implementation of our internal controls with respect to reporting and implemented a remediation plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">During the first quarter of 2022, as part of our remediation plan and procedures, we began implementing the following changes:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Increasing staff resources dedicated to internal controls and reporting including the hiring of a full-time accounting assistant for the CFO who is dedicated to financial reporting;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Specifically delegating roles and responsibilities for each participant in compiling and reviewing our reports including designating a single-point of contact for consolidating data inputs and delegation of key reporting elements to relevant department leads;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Designating an executive team to review all narrative disclosures, including potential changes thereto. The executive team is comprised of the CEO, CFO, Director of Corporate Development, Executive Vice President of Operations, and Chief Legal Counsel;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Establishing a final review process with our Chief Executive Officer and Chief Financial Officer prior to finalizing and filing our reports. At each stage of preparing financial reports the executive team conducts a review of draft materials and discusses the results in telephone conferences; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Establishing an executive review team to approve the final EDGAR version and IXBRL data file for our reports. As described above, the executive team meets and confers to review the final financial reports that are then submitted to the Audit Committee and Board for final approval prior to filing. </td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">During the remainder of 2022, we will continue to implement our remediation plan. In connection with such plan, we expect to further increase our internal corporate resources focused on improving the design, implementation and monitoring of our internal control systems.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="p2" style="display: inline">PART II - OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i1n" style="display: inline">ITEM 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any material legal proceedings or claims involving the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i1a" style="display: inline">ITEM 1A. Risk Factors.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">There are no material changes to the risk factors as previously disclosed in the company’s Form 10-K/A in response to Part I - Item 1A of our annual report filed with the SEC on April 15, 2022.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i2n" style="display: inline">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">2021 Asset Purchase Agreement</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">On November 18, 2021, we entered into the Asset Purchase Agreement with Ainos KY, our majority shareholder. We closed the transaction on January 30, 2022. Pursuant to the Asset Purchase Agreement, we acquired certain intellectual property assets and certain manufacturing, testing, and office equipment for a total purchase price of $26,000,000). As payment of the Purchase Price, at the closing on January 30, 2022, the Company issued to Ainos KY the APA Convertible Note, a convertible promissory note in the principal amount of $26,000,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The principal sum of the APA Convertible Note is payable in cash on January 30, 2027, although we may prepay the APA Convertible Note in whole or in part without penalty. The APA Convertible Note is non-interest bearing. The APA Convertible Note will be automatically converted into shares of our common stock immediately prior to the closing of this offering at a conversion price equal to 80% of the per Unit public offering price.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">2021 – 2022 Ainos KY Working Capital Advances</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In 2021, Ainos KY provided working capital advances in the form of convertible note financing in the aggregate amount of $3,000,000. The working capital convertible notes issued in 2021 bear interest at the AFR short-term rate of 1.85% and may be convertible in whole or in part at a conversion price of $0.20 per share, subject to adjustment. On March 17, 2022, we executed a Promissory Note Extension with Ainos KY dated March 17, 2022, pursuant to which the maturity dates for the convertible notes issued in 2021 to Ainos KY were extended to February 28, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In March 2022, Ainos KY provided us a working capital advance in the form of a non-convertible note financing in the principal amount of $800,000, at a 1.85% per annum interest rate, with a maturity date of February 28, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><em><span style="text-decoration:underline">Convertible Note Offering Pursuant to Regulation S</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company issued convertible notes pursuant to Regulation S as more particularly described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Under a Convertible Note Purchase Agreement dated as of March 31, 2022 by and between the Company and Yun-Han Liao (the “Purchaser”). The Purchaser is the daughter of We Hui-Lan, the Company’s Chief Financial Officer. Pursuant to the Agreement the Purchaser paid a total of $50,000 to the Company in exchange for a Convertible Promissory Note issued by the Company in the principal amount of $50,000 (the “Liao Convertible Note”).</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">Under those certain Convertible Note Purchase Agreements dated as of March 28, 2022 (the “Regulation S Agreements”) by and between the Company and Chih-Cheng Tsai, Ming-Hsien Lee, Yu-Yuan Hsu, and Top Calibre Corporation, a British Virgin Islands company (collectively the “Regulation S Purchasers”). Pursuant to the Regulation S Agreements, the Purchasers paid a total of $850,000 (the “Principal Amount”) to the Company in exchange for Convertible Promissory Notes issued by the Company in the Principal Amount (together with the Liao Convertible Note, the “Convertible Notes”).</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Principal Amount of the Convertible Notes are payable in cash on March 30, 2027, although the Company may prepay the Convertible Notes in whole or in part without penalty. The Convertible Notes are non-interest bearing. If not earlier repaid, the Convertible Notes will be converted into shares of common stock, $0.01 par value per share of the Company, or such other securities or property for which the Convertible Notes may become convertible, immediately prior to the closing of any public offering of the Company’s common stock as result of which the Company’s common stock will be listed on a U.S. stock exchange. The conversion price, subject to certain adjustments, will be eighty percent (80%) of the initial public offering price of the offering.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i3n" style="display: inline">ITEM 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i4n" style="display: inline">ITEM 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Not applicable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i5n" style="display: inline">ITEM 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Not applicable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><span class="atag" id="i6" style="display: inline">ITEM 6. Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>EXHIBIT INDEX</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">  </p><table cellpadding="1" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;width:100%"><tbody><tr style="height:15px"><td colspan="3" style="border-top:#000000 1px solid;border-left:#000000 1px solid;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="4" style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INCORPORATED BY REFERENCE</strong></p></td></tr><tr style="height:15px"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:10%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>EXHIBIT NUMBER</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:26%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>DESCRIPTION</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:10%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FILED WITH </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>THIS FORM 10-K</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FILING DATE WITH SEC</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>FORM</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXH #</strong></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>HYPERLINK TO FILINGS</strong></p></td></tr><tr style="height:15px"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1014763/000101476316000029/exhibit3-i_12312015.htm">3.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1014763/000101476316000029/exhibit3-i_12312015.htm">Restated Certificate of Formation of the Company, dated and filed July 27, 2015</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/30/2016</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3.i.</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Restated Certificate of Formation of the Company, dated and filed July 27, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422005505/aimd_ex32.htm">3.2</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422005505/aimd_ex32.htm">Amended and Restated Bylaws of the Company, effective August 20, 2021</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">4/28/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">S-1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3.2</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422005505/aimd_ex32.htm</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1014763/000095011696000609/0000950116-96-000609.txt">4.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1014763/000095011696000609/0000950116-96-000609.txt">Specimen Common Stock Certificate</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8/8/1996</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SB-2</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">4.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Specimen Common Stock Certificate.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex21.htm">10.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex21.htm">Amended and Restated Asset Purchase Agreement, dated as of January 29, 2022, between Ainos, Inc. and Ainos, Inc.</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2/3/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex21.htm </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex101.htm">10.2</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex101.htm">Convertible Promissory Note, dated as of January 30, 2022, issued by Ainos, Inc.</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2/3/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422001066/aimd_ex101.htm </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10i.htm">10.3</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10i.htm">Non-Convertible Note dated March 4, 2022.</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/17/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10(i)</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10i.htm </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10ii.htm">10.4</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10ii.htm">Note Extension Agreement dated March 17, 2022</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/17/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10(ii)</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10ii.htm </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iii.htm">10.5*</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iii.htm">Employment Agreement by and between Chun-Hsien Tsai and Ainos, Inc. dated March 17, 2022</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/17/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10(iii)</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iii.htm</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iv.htm">10.6*</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iv.htm">Employment Agreement by and between Hui-Lan Wu (aka Celia Wu) and Ainos, Inc. dated March 17, 2022</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/17/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10(iv)</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10iv.htm </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10v.htm">10.7*</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10v.htm">Employment Agreement by and between Chih-Heng Jack Lu and Ainos, Inc. dated March 17, 2022</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">3/17/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10(v)</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422003341/aimd_ex10v.htm</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex21.htm">10.8</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex21.htm">Form of Convertible Note Purchase Agreement</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">4/4/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex21.htm </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex101.htm">10.9</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex101.htm">Form of Convertible Promissory Note</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">4/4/2022</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">8-K</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">10.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/Archives/edgar/data/0001014763/000165495422004526/aimd_ex101.htm </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex241.htm">24.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex241.htm">Power of Attorney by Board of Directors</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex311.htm">31.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex311.htm">Certification of Principal Executive Officer Pursuant to Rule 13a-  14(a) / 15d – 14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">20</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><table cellpadding="1" style="border-spacing:0;font-size:10pt;border-right:#000000 1px solid;border-bottom:#000000 1px solid;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;border-left:#000000 1px solid;padding:1px;width:10%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex312.htm">31.2</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:26%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex312.htm">Certification of Principal Financial Officer Pursuant to Rule 13a-  14(a) / 15d – 14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:10%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex321.htm">32.1</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex321.htm">Certification Of Principal Executive Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex322.htm">32.2</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="https://www.sec.gov/Archives/edgar/data/0001014763/000165495422006967/aimd_ex322.htm">Certification Of Principal Financial Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 Of The Sarbanes-Oxley Act Of 2002</a></p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">100</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL – Related Documents</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.INS</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.SCH</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Schema Document</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.CAL</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Calculation Linkbase</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.DEF</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Definition Linkbase</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.LAB</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Label Linkbase</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.PRE</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Presentation Linkbase</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104.1</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cover Page Interactive Data File</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">X</p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="border-top:#000000 1px solid;padding-bottom:1px;padding-top:1px;padding-left:1px;border-left:#000000 1px solid;padding-right:1px;padding:1px;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">  </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">+ Schedules (as similar attachments) have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">* Indicates a management contract or compensatory plan or arrangement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" id="sin" style="display: inline">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:left;">Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 16, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em> /s/ Chun-Hsien Tsai</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai, Chairman of the Board, </p><p style="font-size:10pt;font-family:times new roman;margin:0px">President, and Chief Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 16, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Hui-Lan Wu</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Hui-Lan Wu, Chief Financial Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"> </p><table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p></body></html>
